

Role of physical therapy in ovarian cancer

Mohammed Sheeba Kauser¹ * Laxmi Devi²

¹Director, ²PHD Scholar ¹AR Physiotherapy Clinic, Andhra Pradesh, India. ²Parul University, Gujarat India

***Corresponding Author: Meenu S**

Email: sheebaishaq.doc@gmail.com

Abstract

Physiotherapy during adjuvant malignant growth treatment have been displayed to increment useful limit, assuage weakness and, help chemotherapy fulfilment. women going through physical therapy for ovarian malignant growth normally have broad pelvic medical procedure followed by focused energy chemotherapy. It is speculated that women with ovarian malignant growth might benefit most from practice intercession during chemotherapy treatment. This could decrease the number and seriousness of chemotherapy-related side-effects and upgrade treatment adherence. Henceforth, the point of this study was to survey practicality and adequacy of role of physical therapy in womens with ovarian disease while going through chemotherapy, as well as pre-post intercession changes in a scope of physical and mental results.

Keywords: Physical therapy, Ovarian cancer, Women

Introduction

Ovarian cancer is the eighth most normal female malignant growth and the 6th most normal reason for cancer-related passing in Australia, with roughly 1,465 new cases analyzed every year.¹ In 2010, in excess of 1,500 females will be determined to have ovarian malignant growth and 850 will bite the dust from the illness. While relative endurance has improved, rate of ovarian disease (roughly 12 cases for every 100,000) has remained somewhat unaltered in the beyond 20 years.² Frequency increments with expanding age and is most predominant in the eighth ten years of female life.³ Generally, five-year endurance is right now 42% yet changes with age, stage and cell kind of ovarian disease.¹

The reasons for ovarian malignant growth remain somewhat less well- laid out than those for more normal disease,⁴ various elements have been perceived as adding to ovarian disease risk. Hereditary and epidemiologic investigations have exhibited that the main gamble factor is hereditary inclination. Five to 10% of ovarian malignant growths are related with transformations in explicit qualities, to some extent, changes in the cancer silencer qualities BRCA1 and BRCA2.⁵ A few attributes have been related with diminished chance of ovarian malignant growth. The utilization of the oral preventative pill makes a solid defensive difference, with risk declining with expanded span of purpose.⁶ This risk decrease is kept up with even a decade after suspension of purpose.⁵ Multiparity likewise is defensive against ovarian disease, as well as tubal ligation and hysterectomy, which on normal has a 67% gamble decrease as seen by accomplice and case-control studies.⁷ The connection between ovarian disease and different qualities including menopause and way of life factors, for example, the utilization of bath powder in genital cleanliness, tobacco smoking, psychotropic drug, dietary variables, caffeine utilization, liquor and heftiness, stay less clear.⁶

Discoveries are additionally muddled regarding the job of active work and hazard of ovarian disease. This could be

because of issues like the utilization of various meanings of actual work, contrasting strategies for estimation and various boundaries of action (for example recurrence, force, length, type). In any case, a meta-analysis of observational investigations exhibited a reverse, yet feeble relationship, between expanding levels of sporting actual work and hazard of ovarian malignant growth.⁸ Proof was, in any case, less reliable for word related and incredible action and for inactive way of behaving.

Diagnosis, Staging and Surgery of Ovarian Cancer

Ovarian disease is the second most normal gynaecologic harm, behind malignant growth of the endometrium.⁹ The signs and side effects of ovarian malignant growth are regularly neglected in light of the fact that they are ambiguous, not entirely obvious and like numerous other natural ailments; as a matter of fact, more than half of the populace mistakenly believes that a pap smear test is intended to identify ovarian disease.¹⁰ Normal side effects experienced incorporate stomach expanding, bulging, and completion, successive pee and additionally copying, stomach uneasiness as well as agony, lower back torment, loss of craving, looseness of the bowels and strange vaginal dying. Actual discoveries are assorted and incorporate a substantial ovarian mass.¹¹ Most ladies are asymptomatic, essentially until the sickness has metastasised, and thus two-thirds are determined to have progressed stage illness.⁶

Ovarian disease is portrayed as a threatening cancer in one or the two ovaries.¹² Ovarian malignant growth can emerge from three cell types, explicitly epithelial, microbe and sex- string stromal cell. The vast majority of cases are named epithelial ovarian disease,¹³ while the leftover are classed as non-epithelial types (microorganism cell malignant growth starts from cells that are bound to shape

eggs inside the ovaries; sex-cord stromal disease starts in the connective cells that keep the ovaries intact and produce female chemicals).¹³ Fallopian tube and peritoneal malignant growths are regularly gathered with ovarian disease as they begin from a similar region and have a similar adjuvant treatment. The examination project shrouded in this theory incorporates ladies determined to have any sort of ovarian, fallopian tube or peritoneal malignant growth (talked about in more detail in strategies).

Assuming ovarian malignant growth is associated on the premise with clinical meeting (actual assessment and comes about because of imaging tests) medical procedure is regularly required for a conclusive determination. An exploratory laparotomy (entry point through stomach divider) is led for histological affirmation, arranging and debulking. The advantages of a medical procedure incorporate decrease of growth load, improvement in disease-related side effects, enhancement of reaction to fundamental chemotherapy and perhaps improvement of patient immunocompetence.¹³ Medical procedure might include evacuation of the uterus (hysterectomy), the two ovaries and fallopian tubes (reciprocal salpingo-oophorectomy) and additionally the greasy defensive tissue covering the stomach organs (omentectomy) as well as lymph hubs in the crotch. Be that as it may, it could be considerably more broad assuming different organs are involved (for example pleura or stomach).¹² The benefit of careful debulking and cytoreduction for cutting edge stage sickness has been examined in a meta-analysis. It was distinguished that for each 10% expansion in cytoreduction there was a related 5.5% increment in middle endurance.¹⁴

Ovarian cancer systematic treatment

Chemotherapy generally starts somewhere in the range of four and a month and a half after medical procedure, but a few examinations have shown a postponed inception of chemotherapy in older ladies of more noteworthy than about a month and a half.¹⁵⁻¹⁶ First-line adjuvant chemotherapy (which is utilized to annihilate or slow the development of the growth) is normally suggested for everything except some stage I cancers and commonly includes a blend of two medications, carboplatin (platinum drugs) and paclitaxel (taxane-based) given intravenously. At the point when patients are not appropriate for blend chemotherapy, whether that be because old enough, being altogether undernourished, clinical comorbidities or lackluster showing status, utilization of a solitary specialist, Carboplatin is for the most part shown.¹³ Consequences of clinical preliminaries attempted in the course of the most recent 30 years support the utilization of six patterns of chemotherapy, at regular intervals as standard therapy for ladies with cutting edge ovarian disease.^{3,11} All the more as of late, nonetheless, intraperitoneal chemotherapy is being utilized as an approach to conveying the medications straightforwardly into the stomach cavity. The stomach depression is the most widely recognized place that ovarian malignant growth will spread. The reasoning for intraperitoneal treatment in ovarian disease is that the

peritoneum gets supported openness to high groupings of antitumor specialists while typical tissues, like the bone marrow, are somewhat saved.¹⁷ Clinical preliminaries have shown that this kind of chemotherapy is appropriate for ladies with stage III ovarian disease, with short of what one centimeter of cancer staying toward the finish of a medical procedure.¹⁷ In especially progressed cases, ladies might require neoadjuvant chemotherapy preceding debulking medical procedure, trying to decrease the size of the cancer. For the 20% to 40% of ladies who don't answer first-line chemotherapy and ladies who have a repeat, second-line treatment might be recommended.¹¹

The objective of treatment is to streamline endurance. Tragically, every treatment system has the gamble of potential physiological and mental unfriendly side-effects that can be the restricting component for finishing chemotherapy. For instance, clinical chemotherapy will be halted or diminished assuming a patient's Eastern Cooperative Oncology Group (ECOG) execution score (a scale used to survey illness movement) is evaluated two (wandering and prepared to do all self-care yet incapable to complete any work exercises, moving around over half of waking hours) or three (able to do just restricted self-care, bound to bed or seat over half of waking hours).²³

Side-Effects of Ovarian Cancer Treatment

The side-effects of foundational treatment might fluctuate broadly and may rely upon elements, for example, the sort of medication or medication blend utilized, portion, strategy for conveyance and patient meds.²⁴ Therapy side-effects including physical and psychosocial concerns have been very much revealed in ovarian malignant growth writing and are examined exhaustively beneath.

Physical

The physical side-effects from medical procedure and adjuvant chemotherapy for ovarian malignant growth incorporate changes to bladder and entrail propensities, neutropenia, hot flushes, torment, transitory going bald, menopausal side effects, body weight vacillations, modifications in taste, expanded hazard of disease and unfortunate rest.^{9,25-26} Sickness and spewing are especially striking side effects, with ovarian malignant growth patients rating these as two of the most over the top feared side-effects of chemotherapy.²⁶ Another side-effect as an outcome of paclitaxel and carboplatin chemotherapy blends is tactile fringe neuropathy.³ Neuropathy has been accounted for in 57% to 92% of all patients treated with cisplatin and 60% of those getting taxanes.²⁷ Much of the time chemotherapy-induced neuropathy is reversible.²⁴ Concerns in regards to cachexia, which is a dynamic weight reduction with exhaustion of fat tissue and skeletal bulk, is additionally an issue for ladies with ovarian disease.²⁸ In cutting edge ovarian malignant growth patients, cachexia is brought about by the metabolic impacts of the expanding cancer masses and entrail deterrent and is responsible for up to 20% of disease passings.²⁸

Cancer-related weakness addresses quite possibly the 'most seen' side effects by lady getting therapy for gynecological disease with its presence seriously slowing down way of life exercises.²⁹ Weakness in ovarian malignant growth patients getting chemotherapy has been found to top roughly seven days after each cycle post-treatment and has solid positive relationships with sickness, despondency and outrage, and negative connections with haematocrit levels.²⁵ Before, individuals with malignant growth were urged to rest and lessen their measure of active work trying to weaken exhausted.³⁰ In any case, such ideas are presently known to intensify side effects and further abatement useful limit.³¹

Psychosocial

The broad medical procedure and forceful chemotherapy regimens, for example, those looked by ladies with ovarian disease have been considered to achieve weakness to mental infirmity.³² Archived mental side-effects of carboplatin incorporate nervousness, discouragement, trouble concentrating, cognitive decline and emotional episodes.²⁵ Both tension and discouragement happen all the more every now and again in patients with disease

Than in everybody, with a few examinations showing 20% to 30% of ovarian disease patients experience moderate to extreme misery and tension.³³⁻³⁶ Mental pain among patients with ovarian disease has been viewed as essentially connected to the quantity of actual side effects ladies experienced.³⁷ Feeling of dread toward repeat or metastases, probability of death and barrenness address different worries adding to mental ill-health.³⁸

Quality of life (QoL)

Previously, examinations would in general assess the length of endurance or the reaction to treatment with little worry for sway on QoL. Presently, QoL is a point of convergence for most clinical preliminaries.³⁹⁻⁴⁰ Despite the fact that there are restricted QoL information accessible following ovarian malignant growth, existing investigations have exhibited decreases in recently analyzed patients⁴¹ and less fortunate by and large QoL for those getting chemotherapy for repetitive sickness contrasted and those getting first-line chemotherapy.⁴² Nonetheless, over the more drawn out term, QoL in ovarian malignant growth patients has been considered 'great' when contrasted and QoL of other disease survivors.⁴³⁻⁴⁴

Role of Physical Therapy

Examinations have recommended that exercise is a basic corresponding/social treatment in the administration of numerous diseases.⁵⁰ Audit studies have found proof steady of the job of practice in weakening a scope of physical and psychosocial issues related with disease or its treatment.⁵¹ During treatment, studies have reliably exhibited a positive relationship of active work with further developed QoL, cardiorespiratory wellness, exhaustion, sorrow, tension,

muscle strength and anthropometric proportions of body weight and muscle versus fat.⁵²

A trailblazer in the field, Maryl Winningham, began to distribute information in 1983 on the job of activity programs for malignant growth patients. Her initial exploration was in the bosom malignant growth populace utilizing aerobic-based intercessions. The mid 1990's saw expanded consideration regarding this field.⁵³ Early work included moderate, managed and solo home-based actual work programs utilizing aerobic-based methods of action, for example, strolling and bike ergometry. Research has kept on advancing additional time with blends of oxygen consuming and obstruction preparing programs being tried with different disease gatherings. Presently in excess of 80 activity studies have been finished, and incorporate mediations of blended practice modes and shifting forces, terms and types of conveyance.⁵⁴

Practice during treatment

A new efficient audit and meta-analysis broke down aftereffects of 82 activity mediation studies directed with malignant growth survivors. Of these examinations, 40% of studies were done during treatment (n=33).⁵⁴ Of those reviews performed during therapy, 79% were led with bosom disease patients, contrasted with just 3% with ovarian malignant growth patients. The mean example size per intercession bunch

Was accounted for as 33, with comparable normal estimated control gatherings (n=32). Most of studies were randomized controlled preliminaries (90%), 88% expected patients to get doctors leeway as well as screening preceding interest and 33% of potential members were rejected in view of past degree of active work. About a third of during treatment intercessions were social change mediations in which the essential point was to increment active work conduct. Subtleties of the activity solution utilized in these investigations are depicted in part two.⁵⁴

From the examinations that have been investigated in these surveys, mediations led during chemotherapy have shown that being dynamic during this period is related with positive outcomes corresponding to body organization, bone mineral thickness, utilitarian limit, insusceptible factors, muscle strength, neutropenia and high-impact limit.^{51,55,56} Decreased effect of infection and treatment-related side effects and side-effects including queasiness, exhaustion, trouble resting, agony and looseness of the bowels, as well as better consistence with treatment systems have likewise been accounted for.⁵⁷ Further developed state of mind and decreased pain, sadness and tension address mental changes related with movement during treatment.^{51,57-59}

Freely or on the whole the advantages of activity are probably going to emphatically impact QoL.⁵³ Alternately, absence of activity during malignant growth treatment can possibly irritate side-effects and instigate loss of capacity, subsequently adding to a decrease of generally QoL.⁶⁰

An investigation of breast malignant growth patients getting adjuvant chemotherapy was quick to consider the impact of activity on chemotherapy completion rates. Ladies (n=242) were arbitrarily appointed to normal consideration, a directed opposition preparing bunch or regulated oxygen consuming activity bunch. Ladies who did oxygen consuming activity three times each week starting with 15 minutes for one to three weeks and expanding to 45 minutes by week 18 had huge upgrades in chemotherapy finishing rates (74%) contrasted and rates in the benchmark group (66%).⁶¹ Ladies in the opposition preparing bunch were approached to practice three times each week performing 8-12 reiterations for two arrangements of nine distinct activities (of assessed 1 RM), and furthermore showed enhancements in chemotherapy finishing rates (78% finished chemotherapy). Early discontinuance of chemotherapy has been displayed to impact the capacity of the medications to successfully treat the sickness, thus affecting on endurance.

Practice following treatment

Test review looking at the impact of activity following disease treatment have been broadly introduced. Gains in strength, high-impact limit and adaptability, alongside upgrades in safe capacity, circulatory strain and body structure have all been connected with practice programs following disease treatment.^{48,51,55,60,62} Enhancements in mental well-being, battling soul, mind-set status, self-esteem, and self-perception and decreases in nervousness, dozing issues and sadness have additionally been noticed.^{48,51,55,60,62}

Malignant growth bunches surveyed

Without a doubt, breast malignant growth has been the most well-known disease type concentrated in cancer-related practice intercession preliminaries. In an audit paper, of the 18 investigations attempted during therapy, nine solely elaborate ladies with breast disease and keeping in mind that three others incorporated a blended malignant growth bunch, ladies with breast malignant growth included 57% of the example.⁵⁵ Other malignant growth bunches researched incorporate colorectal,⁶³ lung⁶⁴, head and neck,⁶⁵ hematological,⁵⁶ prostate⁶⁶ and gynecological disease (counting ovarian and cervical),⁶⁷ albeit the assortment of proof encompassing activity and these disease bunches is more restricted. A new precise audit (embraced as a component of this experts and right now under survey; Appendix A) assessed the degree to which ladies with gynecological disease have been associated with practice intercession preliminaries during and additionally following malignant growth treatment. Of the 12 investigations recognized (92% of which included blended malignant growth types) just 10% of the absolute example of members (n=212) were ladies determined to have gynecological disease (ovarian, endometrial or cervical). Further, there has just been one activity mediation preliminary that has involved just a gynecological malignant growth (endometrial) accomplice.⁶⁸

We have a lot to learn here and in the plan of future gynecological malignant growth and exercise mediation studies. While it is critical to recognize what has been gained from the more extensive activity and malignant growth setting, given the extreme idea of ovarian disease therapy it can't be expected that exercise programs intended for breast disease patients can be applied to ovarian disease patients without changes. Future exploration, as 'confirmation of idea', is expected to all the more likely comprehend how well outcomes found in other malignant growth accomplices are generalisable to ladies with ovarian disease.

Exercise Prescription During Treatment

In spite of the wealth of actual work studies led during therapy, the exact activity remedy, comparable to ideal kind, recurrence, span and power for malignant growth patients overall stay muddled.

Mode

The most widely recognized practice mediations surveyed are aerobic-based, explicitly utilizing a cycle ergometer as well as strolling modes, either alone or in blend with opposition preparing.^{50, 51, 57-60} The method of movement is for the most part steady for both intercession during and post treatment. Strolling and accelerating exercise have been noted as the most secure modalities.³¹ Strolling is an action individuals perform day to day and includes the utilization of significant muscle gatherings. It is additionally a helpful method of activity for a great many people, regardless old enough and sickness status and requires no gym equipment and has restricted related cost.⁶⁰ In a review analyzing exercise inclinations in 386 endometrial disease survivors, 69% showed their favored method of movement was strolling.⁶⁹ Actual work inclinations for ovarian disease survivors (postal review of 359 ladies) were comparable, with 63% demonstrating strolling as their ideal method of activity.⁷⁰ Additionally, strolling was the leaned toward method of action in a home-based practice program during chemotherapy treatment in patients with strong cancers.⁶⁷

Type of conveyance, recurrence and length

Practice prescriptive attributes differ across studies with mediations during treatment going from totally directed, or totally solo home-based programs.⁵⁵ Practice mediation lengths range somewhere in the range of two weeks to one year,⁵¹ with the recurrence of meetings going from two meetings per day to six meetings each week⁵¹ and the normal meeting length is 30-45 minutes.⁵⁴ The most recent activity remedies rules for malignant growth patients, from the Australian Exercise and Sports Science Association (ESSA, recently known as the Australian Association for Exercise and Sports Science) position stand (2009) is no different for patients going through treatment or following treatment. It prescribes somewhere around 20 to 30 minutes of constant high-impact practice be attempted for a recurrence of three to five times each week.⁶⁰ Be that as it may, the accentuation for deconditioned patients has been on oxygen consuming movement a few times each day for more limited sessions

including rest spans.⁷¹ Thus, the suggested span can be collected in one meeting each day or amassed throughout a day with benefits accomplished regardless of how length is gathered. Movement of activity is regularly recommended through a mix of expanded span and recurrence prior to expanding power level. Movement for certain people, especially during times of treatment, could comprise upkeep of pre-treatment practice levels.⁶⁰

Randomized, controlled preliminaries of activity for malignant growth patients during therapy have detailed different powers going from at least half, up to 90% assessed most extreme pulse (HRmax).^{51,55}

Conclusion

Unlike other malignancies or cancer, females with ovarian disease taking part in standard activity during treatment might encounter decreases in the seriousness of side-effects, upgrades in treatment consummation rates and improvements in mental well-being. Nonetheless, the coordinated factors in selecting and holding ovarian disease patients into an activity intercession during chemotherapy have not yet been investigated. Contrasted and the malignant growth types all the more regularly explored in practice mediation preliminaries, ovarian disease patients are dominantly late stage finding, have high gamble of repeat and go through significant stomach a medical procedure as an essential type of therapy includes, Patients additionally normally go through numerous regimens of chemotherapy however may encounter decreases in arranged chemotherapy because of the presence and force of side effects. While these distinctions might make remembering these patients for an activity intercession concentrate on more intricate, they likewise address reasons concerning why exercise might be especially valuable to this partner. Nonetheless, until now, ovarian malignant growth patients have not been only examined in any activity mediation study.

Source of Funding

None.

Conflict of Interest

None.

References

1. Australian Institute of Health and Welfare & National Breast and Ovarian Cancer Centre. Ovarian Cancer in Australia: an overview, 2010. Canberra: Australian Institute of Health and Welfare & National Breast and Ovarian Cancer Centre; 2010.
2. Kricke A. Ovarian Cancer in Australian women. National Ovarian Cancer Centre February 2002. National Breast Cancer Centre 2002.
3. National Comprehensive Cancer Network . Practical guidelines in Oncology Ovarian Cancer Version 1 2009. National Comprehensive Cancer Network 2009.
4. Kramer M, Wells C. Does physical activity reduce risk of estrogen-dependent cancer in women? *Med Sci Sports Exerc* 1996; 28(3): 322-34.
5. Salehi F, Dunfield L, Phillips K, et al. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. *J Toxicol Environ Health* 2008; 11:301-321.
6. Holscheider C, Berek J. Ovarian Cancer: Epidemiology, biology, and prognostic factors. *Semin Surg Oncol* 2000; 19:3-10.
7. Miracle-McMahill H, Calle E, Kosinski A, et al. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. *Am J Epidemiol* 1997;145(4) 349-57.
8. Olsen C, Bain C, Jordan S, et al. Recreational physical activity and epithelial ovarian cancer: A case-control study, systematic review, and meta-analysis. *Cancer Epidemiol Biomark Prev* 2007; 16(11): 2321-30.
9. Goff B, Mandel L, Drescher C, et al. Development of an ovarian cancer symptom index possibilities for earlier detection. *Cancer* 2007; 109(2): 221-27.
10. Watkins T, Maxeiner A. Musculoskeletal effects on ovarian cancer and treatment: a physical therapy perspective. *Rehabil Oncol* 2003; 21 (2): 12-7.
11. Hennessy B, Coleman R, Markman M. Ovarian Cancer. *Lancet*, 2009; 374(9698) 1371-82.
12. The Cancer Council. Understanding Ovarian Cancer – a guide for women with cancer, their families and friends. The Cancer Council New South Wales, 2007.
13. Thursfield V, Chionh F, Giles G. Canstat – Ovarian Cancer. Cancer Epidemiology Centre Cancer Council Victoria 2007.
14. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *J Clin Oncol* 2002; 20:1248-59.
15. Wright D, Doan T, McBride R, et al. Variability in chemotherapy delivery forelderly women with advanced stage ovarian cancer and its impact on survival. *Br J Cancer* 2008; 98(7): 1197-1203.
16. Aletti GD, Long HJ, Podratz KC, et al. Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer. *Gynecol Oncol* 2007;104:212-6.
17. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *New Engl J Med* 2006;354(1) 34-43.
18. Beesley V, Hayes S, Newton M, et al. Limited walking capacity is a predictor of deteriorating patient reported outcomes, chemotherapy incompleteness and reduced survival in women with ovarian cancer 2010 (In Preparation).
19. Hirria A, Leung D, Trainor K, et al. Factor influencing treatment patterns of breast cancer patients age 75 and older. *Crit Rev Oncol Hematol* 2003; 46(2)121-6.
20. Law CC, Fu YT. Postoperative adjuvant 5-Fluorouracil plus levamisole chemotherapy for stage III colon carcinoma: 7-year experience in a single institution. *J Hong Kong Coll Radiol* 2002;5:97-104.
21. Markman M, Bundy B, Alberts D, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the gynecologic oncology group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. *J Clin Oncol* 2001; 19 (4): 1001-7.
22. Liu M, Chien L, Tai C, et al. Effectiveness of traditional Chinese medicine for liver protection and chemotherapy completion among cancer patients. 2009 Open Access article.
23. Oken M, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*. 1982;5(6):649-55.
24. Quasthoff S, Hartung H. Chemotherapy-induced peripheral neuropathy. *J Neurol* 2002; 249(1) 9-17.
25. Buckingham R, Fitt J, Sitzia J. Patients' experiences of chemotherapy: side-effects of carboplatin the treatment of carcinoma of the ovary. *European Journal of Cancer Care* 1997; 6:59-67.
26. Sun C, Bodurka D, Weaver C, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. *Supp Care Cancer* 2005;

- 13:219-27.
27. Armstrong T, Almadrones L, Gilbert M. Chemotherapy-induced peripheral neuropathy. *Oncol Nurs Forum* 2005; 32 (2): 305-11.
 28. Tisdale M. Cachexia in cancer patients. *Nat Rev* 2002; 2: 862-71.
 29. Donovan HS, Ward S. Representations of fatigue in women receiving chemotherapy for gynecologic cancers. *Oncol Nurs Forum* 2005; 32 (1)113-6.
 30. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults (review). *Cochrane Database Systematic Rev* 2008.
 31. Lucía A, Earnest C, Pérez M. Cancer-related fatigue: can exercise physiology assist oncologists? *Lancet Oncol* 2003; 4: 616-25.
 32. McCorkle R, Pasacreta J, Tang S. The silent killer: Psychological issues in ovarian cancer. *Holistic Nurs Pract* 2003; 17(6):300-8.
 33. Norton T, Manne S, Rubin S, et al. Prevalence and predictors of psychological distress among women with ovarian cancer. *J Clin Oncol* 2004; 22:919-26.
 34. Kornblith A, Thaler H, Wong G, et al. Quality of life of women with ovarian cancer. *Gynecol Oncol* 1995; 59: 231-42.
 35. Bodurka-Bervers D, Basen-Engquist K, Carmack C, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. *Gynecol Oncol* 2000; 78, 302-8.
 36. Parker P, Kudelka A, Basen-Engquist K, et al. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. *Gynecol Oncol* 2006; 100:(3) 495-500.
 37. Portenoy R, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. *Eur J Cancer* 1994; 30(9): 1326-36.
 38. Lockwood-Rayermann S. Survivorship issues in ovarian cancer: A review. *Oncol Nurs Forum* 2006; 33(3): 553-62.
 39. KS. Exercise in cancer survivors: an overview of research. *Med Sci Sports Exer* 2003; 35:(11) 1846-52.
 40. Speck RM, Courneya KS, Masse LC, et al. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. *J Cancer Survivorship* 2010; 4:(1) 87-100.
 41. Galvao DA, Newton RU. Review of exercise intervention studies in cancer patients. *J Clin Oncol* 2005; 23: 899-909.
 42. Hayes S, Davies PSW, Parker T, et al. Total energy expenditure and body composition changes following peripheral blood stem cell transplantation and participation in an exercise programme. *Bone Marrow Transplant* 2003; 31:(5)331-8.
 43. Conn VS, Hafdahl AR, Porock DC, et al. A meta-analysis of exercise interventions among people treated for cancer. *Supp Care Cancer* 2006; 14:(7) 699-712.
 44. Schmitz KH, Holtzman J, Courneya KS, et al. Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. *Cancer Epidemiol, Biomark Prev* 2005; 14(7):1588-95.
 45. Courneya KS, Friedenreich CM. Physical exercise and quality of life following cancer diagnosis: a literature review. *Ann Behav Med* 1999; 21(2):171-9.
 46. Hayes S, Spence R, Galvão D, et al. Australian Association for Exercise and Sport Science position stand: Optimising cancer outcomes through exercise. *J Sci Med in Sport* 2009; 12:(4) 428-43.

How to cite: Kauser M S Devi L et al. Role of physical therapy in ovarian cancer *IP Journal of Urology, Nephrology & Hepatology Science*. 2021;4(4):. 101-6